NVO Jan 2026 180.000 call
| Previous close | 11.25 |
| Open | 10.80 |
| Bid | 9.50 |
| Ask | 10.30 |
| Strike | 180.00 |
| Expiry date | 2026-01-16 |
| Day's range | 10.80 - 11.25 |
| Contract range | N/A |
| Volume | |
| Open interest | 178 |
ZacksPharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
GlobeNewswireNovo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiate
Zacks4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
